Anavex Life Sciences Announces U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia

January 17, 2024

https://www.globenewswire.com/news-release/2024/01/16/2809762/29248/en/Anavex-Life-Sciences-Announces-U-S-Phase-2-Clinical-Trial-of-ANAVEX-3-71-in-Schizophrenia.html

Placebo-controlled Phase 2 trial cleared by the FDA – Trial to begin in Q2 2024

Trial to include Schizophrenia validated clinical outcomes PANSS and EEG/ERP biomarkers

Read more at globenewswire.com

Related news for (AVXL)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.